Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAP score prediction study of Octagam 5% in early relapsing multiple sclerosis
2012-005086-12Phase 3Terminated
- Sponsor
- Octapharma
- Start
- May 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of Human normal immunoglobulin G, interferon beta-1a, interferon beta-1b and glatiramer acetate in multiple sclerosis (MS) (2 arms), sponsored by Octapharma. Primary endpoint: Annualized relapse rate difference by HAP-predicted response status in Octagam-treated patients. Started May 2013; status: terminated.
02
Drugs
Human normal immunoglobulin Ginterferon beta-1ainterferon beta-1bglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-005086-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005086-12.